Pleased to share our recent Journal of Biological Chemistry article describing the mechanism of UM171. I would like to thank all co-authors Zemaitis_K,sudip ghosh Hansson Lab at Lund Stem Cell Center
#Targeted_protein_degradation , #UM171 , #RCOR3 , #Haematopoietic_stem_cells
#ELM2

jbc.org/article/S0021-…

Great talk from my friend and colleague Filippo Milano MD, PhD from Fred Hutchinson Cancer Center presenting the data from the #um171 trial. #cordblood , #ASH23 , #TeamMolosso

The stem cell-supporting small molecule UM171 triggers Cul3-KBTBD4-mediated degradation of ELM2 domain-harboring proteins lnkd.in/dGzTTXSd

#PRIX | 👩‍🔬👨‍🔬 Les professeurs de la Faculté de Faculté de médecine Sylvie Mader et Guy Sauvageau reçoivent un prix de la Société canadienne pour les biosciences moléculaires.

Research Canada #médecine #UM171 #cancerdusein
bit.ly/49MnCPL

Our latest research article is highlighted at Lund Stem Cell Center news. It's also my first senior author paper from my research program on targeted protein degradation.
#Targeted_Protein_Degradation , #UM171 , #RCOR3 , #ELM2 , #Blood_Stem_Cells

Read the publication that made the Blood Advances journal cover authored by our Sidra Medicine scientists:
CD14 /CD31 monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII ashpublications.org/bloodadvances/…

A UM171 cord transplant has a higher progression-free and GVHD-free relapse-free survival compared with a MUD transplant. loom.ly/D12KzKE #clinicaltrialsandobservations #transplantation

ExCellThera announces #research published in Blood that expands on #UM171 mechanism of action and highlights its potential to create improved blood stem cell therapies, including our UM171 Cell Therapy. excellthera.com/news/excellthe…
#celltherapy

New article posted on Rare Disease Advisor #SCD : 'Adding UM171 to Gene Therapy for SCD Improves HSC Outcomes.' Read the full article here: buff.ly/40z6OZx #sicklecell #haematology #raredisease

UM171 mediates concomitant CoREST/MYC degradation, which requires CUL3KBTBD4 ubiquitin ligase activation. ow.ly/7H4B50QNX9E #hematopoiesisandstemcells

ExCellThera's Chief Scientific Officer, Guy Sauvageau, will present on advances of blood stem cell expansion using #UM171 ,  leading to impressive clinical results at #EBMT24 in Glasgow, Scotland. excellthera.com/news/excellthe…

🧪A study by Lund Stem Cell Center researchers in Journal of Biological Chemistry decodes the inner workings of #UM171 , a molecule that supports blood stem cells. Discover new insights into how it breaks down disease-causing proteins & expands blood cells👇
stemcellcenter.lu.se/article/decodi…
Subramaniam Lab | Medicinska fakulteten, Lunds universitet

From our Evidence Alert this month: Cohen et al in Blood Advances on Improved Outcomes of UM171-Expanded #Cord Blood Transplantation Compared with Other Graft Sources: Real-World Evidence
stemcellevidence.com/alerts/article…
#BMT #StemCellEvidence

ฅNya! Here's the latest 🗞 from [ Blood ]: ' KBTBD4-mediated Reduction of MYC Is Critical for Hematopoietic Stem Cell Expansion upon UM171 Treatment' 🔗: sciencedirect.com/science/articl…

UM171 improves outcomes of cord-blood transplants in high-risk leukemia #HodgkinLymphoma #HodgkinsLymphoma #MultipleMyeloma [Video] Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines studies investigating… dlvr.it/T0gVWn

La découverte de la molécule UM171, prouve que les vrais chercheurs travaillent dans des universités… pas chez Big Pharma. Quelle découverte génial au potentiel incroyable

Exciting news! ⬇️ Congratulations to ExCellThera on positive phase 2 study results from UM171 cell therapy. SCN is proud to have provided support for the discovery, development, and prior clinical testing of a blood stem cell expansion program since 2003. #BloodCancers #Leukemia

Here we demonstrate that UM171 induces a rapid degradation of ELM2 domain containing proteins RCOR1 and RCOR3.

🇨🇦 #Canada / 🇺🇸 #US A : Des chercheurs canadiens et #US ont identifié une molécule, #UM171 , qui permet de multiplier jusqu'à 80 fois les cellules souches du sang de cordon pour le traitement des leucémies aiguës et des myélodysplasies à risque élevé de rechute.

🔬 The proprietary small molecule UM171 has the potential to create improved HSC therapies through efficient HSC expansion in patients with high-risk leukemias and myelodysplasias, according to a study published in Blood Journal.

📰 buff.ly/43cN7rB